Modelling individual infancy growth trajectories to predict excessive gain in BMI z-score: a comparison of growth measures in the ABCD and GECKO Drenthe cohorts.

Body mass index Body-weight trajectory Child Growth Infant Mass screening Model Overweight Prediction Risk

Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
05 Dec 2023
Historique:
received: 23 05 2023
accepted: 28 11 2023
medline: 7 12 2023
pubmed: 6 12 2023
entrez: 5 12 2023
Statut: epublish

Résumé

Excessive weight gain during childhood is a strong predictor for adult overweight, but it remains unknown which growth measures in infancy (0-2 years of age), besides predictors known at birth, are the strongest predictors for excessive weight gain between 2 and 5-7 years of age. The Amsterdam Born Children and their Development (ABCD) study formed the derivation cohort, and the Groningen Expert Center for Kids with Obesity (GECKO) Drenthe study formed the validation cohort. Change (Δ) in body mass index (BMI) z-score between 2 and 5-7 years was the outcome of interest. The growth measures considered were weight, weight-for-length (WfL), and body mass index (BMI). Formats considered for each growth measure were values at 1, 6, 12, and 24 months, at the BMI peak, the change between aforementioned ages, and prepeak velocity. 10 model structures combining different variable formats and including predictors at birth were derived for each growth measure, resulting in 30 linear regression models. A Parsimonious Model considering all growth measures and a Birth Model considering none were also derived. The derivation cohort consisted of 3139 infants of which 373 (11.9%) had excessive gain in BMI z-score (> 0.67). The validation cohort contained 2201 infants of which 592 (26.9%) had excessive gain. Across the 3 growth measures, 5 model structures which included measures related to the BMI peak and prepeak velocity (derivation cohort area under the curve [AUC] range = 0.765-0.855) achieved more accurate estimates than 3 model structures which included growth measure change over time (0.706-0.795). All model structures which used BMI were superior to those using weight or WfL. The AUC across all models was on average 0.126 lower in the validation cohort. The Parsimonious Model's AUCs in the derivation and validation cohorts were 0.856 and 0.766, respectively, compared to 0.690 and 0.491, respectively, for the Birth Model. The respective false positive rates were 28.2% and 20.1% for the Parsimonious Model and 70.0% and 74.6% for the Birth Model. Models' performances varied significantly across model structures and growth measures. Developing the optimal model requires extensive testing of the many possibilities.

Sections du résumé

BACKGROUND BACKGROUND
Excessive weight gain during childhood is a strong predictor for adult overweight, but it remains unknown which growth measures in infancy (0-2 years of age), besides predictors known at birth, are the strongest predictors for excessive weight gain between 2 and 5-7 years of age.
METHODS METHODS
The Amsterdam Born Children and their Development (ABCD) study formed the derivation cohort, and the Groningen Expert Center for Kids with Obesity (GECKO) Drenthe study formed the validation cohort. Change (Δ) in body mass index (BMI) z-score between 2 and 5-7 years was the outcome of interest. The growth measures considered were weight, weight-for-length (WfL), and body mass index (BMI). Formats considered for each growth measure were values at 1, 6, 12, and 24 months, at the BMI peak, the change between aforementioned ages, and prepeak velocity. 10 model structures combining different variable formats and including predictors at birth were derived for each growth measure, resulting in 30 linear regression models. A Parsimonious Model considering all growth measures and a Birth Model considering none were also derived.
RESULTS RESULTS
The derivation cohort consisted of 3139 infants of which 373 (11.9%) had excessive gain in BMI z-score (> 0.67). The validation cohort contained 2201 infants of which 592 (26.9%) had excessive gain. Across the 3 growth measures, 5 model structures which included measures related to the BMI peak and prepeak velocity (derivation cohort area under the curve [AUC] range = 0.765-0.855) achieved more accurate estimates than 3 model structures which included growth measure change over time (0.706-0.795). All model structures which used BMI were superior to those using weight or WfL. The AUC across all models was on average 0.126 lower in the validation cohort. The Parsimonious Model's AUCs in the derivation and validation cohorts were 0.856 and 0.766, respectively, compared to 0.690 and 0.491, respectively, for the Birth Model. The respective false positive rates were 28.2% and 20.1% for the Parsimonious Model and 70.0% and 74.6% for the Birth Model.
CONCLUSION CONCLUSIONS
Models' performances varied significantly across model structures and growth measures. Developing the optimal model requires extensive testing of the many possibilities.

Identifiants

pubmed: 38053084
doi: 10.1186/s12889-023-17354-4
pii: 10.1186/s12889-023-17354-4
pmc: PMC10698894
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2428

Subventions

Organisme : ZonMw
ID : 2100.0076, 92003489
Pays : Netherlands

Informations de copyright

© 2023. The Author(s).

Références

Int J Epidemiol. 2008 Jun;37(3):486-9
pubmed: 18238823
Pediatr Obes. 2020 Aug;15(8):e12635
pubmed: 32237216
BMC Med. 2022 Apr 14;20(1):156
pubmed: 35418073
Obes Rev. 2005 May;6(2):143-54
pubmed: 15836465
Front Pediatr. 2021 Jan 12;8:581461
pubmed: 33511092
Clin Endocrinol (Oxf). 2022 Mar;96(3):288-301
pubmed: 34750858
Diagn Progn Res. 2019 Oct 04;3:18
pubmed: 31592444
Front Pediatr. 2021 May 12;9:665655
pubmed: 34055698
PLoS One. 2010 Nov 12;5(11):e13966
pubmed: 21103047
J Clin Endocrinol Metab. 2015 Apr;100(4):1551-60
pubmed: 25636051
Int J Obes (Lond). 2009 Aug;33(8):929-37
pubmed: 19564879
Int J Obes (Lond). 2015 Apr;39(4):586-92
pubmed: 25435256
Horm Res Paediatr. 2018;90(6):358-367
pubmed: 30739117
PLoS One. 2014 Mar 27;9(3):e93581
pubmed: 24676281
Int J Epidemiol. 2011 Oct;40(5):1176-86
pubmed: 20813863
Obes Rev. 2018 Mar;19(3):302-312
pubmed: 29266702
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Obes Rev. 2008 Sep;9(5):474-88
pubmed: 18331423
BMJ. 2000 Apr 8;320(7240):967-71
pubmed: 10753147
Curr Obes Rep. 2015 Sep;4(3):363-70
pubmed: 26627494
BMJ. 2001 Apr 21;322(7292):949-53
pubmed: 11312225
BMC Med. 2020 May 11;18(1):105
pubmed: 32389121
N Engl J Med. 1997 Sep 25;337(13):869-73
pubmed: 9302300
Semin Perinatol. 2010 Jun;34(3):207-10
pubmed: 20494737
PLoS One. 2013 Aug 07;8(8):e71183
pubmed: 23940713
N Engl J Med. 2018 Oct 04;379(14):1303-1312
pubmed: 30281992
N Engl J Med. 2005 Oct 27;353(17):1802-9
pubmed: 16251536
Adv Nutr. 2017 Sep 15;8(5):718-727
pubmed: 28916572
BMJ. 2005 Oct 22;331(7522):929
pubmed: 16227306
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Obes Rev. 2012 Apr;13(4):347-67
pubmed: 22171945
Mayo Clin Proc. 2017 Feb;92(2):251-265
pubmed: 28065514
Pediatrics. 2007 Dec;120 Suppl 4:S164-92
pubmed: 18055651
BMC Pediatr. 2004 Mar 12;4:6
pubmed: 15113440
J Pediatr. 2013 Feb;162(2):287-92.e2
pubmed: 22985721
Ann Transl Med. 2016 May;4(9):174
pubmed: 27275487
Pediatr Obes. 2012 Aug;7(4):284-94
pubmed: 22715120

Auteurs

Anton Schreuder (A)

Department of Public and Occupational Health, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, The Netherlands. antoniusschreuder@gmail.com.
Leiden Institute of Advanced Computer Science, Leiden University, Leiden, The Netherlands. antoniusschreuder@gmail.com.

Eva Corpeleijn (E)

Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Tanja Vrijkotte (T)

Department of Public and Occupational Health, Amsterdam UMC, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH